The Quarterly Report did have some key lines that sound promising
Blood test for breast cancer should be clinically available in 2024
Laboratory expected to be commissioned and operational in early May 2023
BCAL is continuing to meet with and assess potential partners in the US to further the commercialisation of
the BCAL test and take the test to the US market.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
Add BDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.00M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.3¢ | $101.2K | 959.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1111472 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 519555 | 3 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.5¢ | 10.8¢ | 10.0¢ | 668982 | ||
| Last updated 15.51pm 17/06/2024 ? | |||||
| BDX (ASX) Chart |
